Teva Pharmaceutical Industries Ltd. Form 8-K Filing

This filing summarizes Teva Pharmaceutical Industries Ltd.'s 8-K report dated September 3, 2026. Key financial details include cumulative goodwill impairment as of December 31, 2025, 2024, and 2023, amounting to approximately $29.6 billion, $29.6 billion, and $28.3 billion, respectively. Revenues from licensing arrangements in the United States segment were primarily driven by a $500 million milestone payment received in Q4 2025 for the initiation of Phase 3 studies for duvakitug (anti-TL1A). The report also details various debt repayments and issuances throughout 2025, including the repayment of several senior notes and the issuance of new senior notes totaling $700 million, €1,000 million, and $500 million with varying interest rates and due dates. Contingent consideration liabilities, foreign currency translation adjustments, and hedge accounting for cross-currency interest rate swaps are also discussed. The company has engaged in various hedging strategies using foreign exchange contracts to mitigate currency exposure on projected revenues and expenses. Significant events in 2025 include the repayment of multiple senior notes and a cash tender offer to extinguish a substantial principal amount of other senior notes, resulting in a $10 million loss. Sustainability-linked bonds with potential premium payments and interest rate adjustments based on performance targets are also a feature of the company's financing.